New hope: short TB prevention for kids with HIV
NCT ID NCT05122767
First seen Jan 07, 2026 · Last updated May 17, 2026 · Updated 22 times
Summary
This study tests a once-weekly, 12-dose treatment for latent tuberculosis (TB) in children and teens with HIV. The goal is to see if it is safe and how it interacts with their HIV medication dolutegravir. About 92 participants aged 3 months to 17 years will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital
Klerksdorp, North West, 2571, South Africa
-
The Aurum Institute: Pretoria Clinical Research Centre
Pretoria, Gauteng, 0087, South Africa
Conditions
Explore the condition pages connected to this study.